Premium
Study of the bioavailability of pindolol in malabsorption syndromes.
Author(s) -
Evard D,
Aubry JP,
Quintrec Y,
Cheymol G,
Cheymol A
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02518.x
Subject(s) - bioavailability , pindolol , pharmacokinetics , malabsorption , medicine , oral administration , gastroenterology , volume of distribution , absorption (acoustics) , pharmacology , propranolol , physics , acoustics
Pindolol kinetics and bioavailability were studied after a single dose (oral 5 mg; intravenous 3 mg) in nine patients with malabsorption (two with villous atrophies, seven with short bowel syndromes) and in six healthy volunteers. After oral administration no significant differences were observed in bioavailability (59.4 +/‐ 6.2% in patients vs 79.5 +/‐ 8.6% in controls) and for most plasma and urinary pharmacokinetic parameters between the experimental and control groups as a whole. However, detailed analysis revealed decreased absorption for pindolol in two out of nine patients. After i.v. administration, apparent distribution volume was smaller (V: 2.10 +/‐ 0.25 l kg‐1 vs 3.05 +/‐ 0.31 l kg‐1) and global elimination constant was larger (ke: 1.43 +/‐ 0.46 h‐1 vs 0.56 +/‐ 0.10 h‐1), in patients with malabsorption than in controls (P less than 0.05). The smaller weight of patients and pharmacokinetic modifications due to the pathology could account for this.